⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Shanghai Henlius Biotech, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Shanghai Henlius Biotech, Inc.
↗Shanghai, China
Shanghai Henlius Biotech, Inc. is a global, innovation-driven biopharmaceutical company founded in 2010. It focuses on the development, manufacturing, and commercialization of high-quality, affordable biologic therapies, primarily in the fields of oncology, autoimmune diseases, and ophthalmic diseases.
The company operates an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, and manufacturing. Henlius has established a significant global presence with products approved in over 60 countries and regions, including multiple approvals from the U.S. FDA and the European Commission.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$927M
Founded:2010
Ownership:public
Status:operating
FUNDING
Investors:Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
STOCK
Exchange:SEHK
Ticker:2696.HK
Market Cap:$5.18B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:mAb, ADC, Bispecific antibody, Fusion protein, Small molecule
Active Trials:30
Trial Phases:-
FDA Approvals:4
EMA Approvals:4
CORPORATE STRUCTURE
Key Partnerships:Shanghai Fosun Pharmaceutical, Abbott, SVAX
COMPETITION
Position:Leader
Competitors:Junshi Biosciences, BeiGene, Hengrui Medicine
LEADERSHIP
Key Executives:
ZHANG Wen Jie - Chairman of the Board
Scientific Founders:Dr. Scott Liu, Dr. Weidong Jiang
LINKS
Website:henlius.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Shanghai Henlius Biotech, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.